Top Markets
#1 Akedo Akedo +73.71%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +48.71%
#4 Cross Cross +43.52%
#5 Black Phoenix Black Phoenix +33.78%
#6 Cap Cap +25.61%
#7 Velvet Velvet +25.32%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.62%
#9 DoubleZero DoubleZero +12.53%
#10 Humanity Humanity +10.30%
Coin of the day
Akedo Akedo
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Aceragen, Inc. Aceragen, Inc.

Aceragen, Inc.

ACGN
Rang în acțiuni #39039
Aceragen, Inc., a biopharmaceutical firm in its clinical development phase,... Aceragen, Inc., a biopharmaceutical firm in its clinical development phase, operates out of Exton, Pennsylvania, and was founded in 1989. The company, which transitioned from Idera Pharmaceuticals, Inc. and adopted its current name in January 2023, concentrates on the discovery, advancement, and bringing to market of therapeutic agents for uncommon lung and autoimmune conditions exclusively within the United States. Its product development pipeline includes ACG-701, currently undergoing Phase 2 clinical evaluation for both cystic fibrosis pulmonary exacerbations and melioidosis, as well as ACG-801, which is being developed to address Farber disease. Moreover, Aceragen maintains a partnership and option agreement with Scriptr Global, Inc. This collaboration aims to pinpoint, research, and cultivate gene therapy options intended for the management, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia.
Preț acțiune
$0.38
Ultima sincronizare: 2023-09-01
Capitalizare de piață
$677.16K
Schimbare (1 zi)
0.00%
Schimbare (1 an)
0.00%
Țară
US
Tranzacționează Aceragen, Inc. (ACGN)

Categorie

Healthcare
Venituri pentru Aceragen, Inc. (ACGN)
Venituri în Aug 2026 TTM: 0
Conform celor mai recente rapoarte financiare ale Aceragen, Inc., venitul actual al companiei (TTM) este 0. În anul 2026, compania a avut un venit de 0 egal cu venitul din anul 2026, care a fost de 0. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Aceragen, Inc. din 2026 până în 2026
Venituri la sfârșitul fiecărui an
An Venituri Schimbă
Nu sunt suficiente date pentru perioada selectată.
Venituri pentru companii similare sau concurente
Companie Venituri Diferență de venituri Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE